3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA

About this update from 3d Medicines, Inc.

3D Medicines Inc HKEX:1244:ENVAFOLIMAB SUPPLEMENTAL APPLICATION FOR CONDITIONAL-TO-REGULAR APPROVAL TRANSITION ACCEPTED BY NMPA

View stock analysis, news, and events for 3d Medicines, Inc.